Calamos Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.72M | Hold |
98,472
| – | – | 0.02% | 553 |
|
|
2026
Q1 | $3.62M | Sell |
98,472
-12,760
| -11% | -$605K | 0.01% | 600 |
|
|
2025
Q4 | $5.66M | Sell |
111,232
-395
| -0.4% | -$20.2K | 0.02% | 510 |
|
|
2025
Q3 | $6.19M | Hold |
111,627
| – | – | 0.02% | 519 |
|
|
2025
Q2 | $7.7M | Sell |
111,627
-377
| -0.3% | -$25.6K | 0.03% | 475 |
|
|
2025
Q1 | $7.78M | Sell |
112,004
-34,862
| -24% | -$2.88M | 0.03% | 444 |
|
|
2024
Q4 | $12.6M | Sell |
146,866
-73,753
| -33% | -$7.98M | 0.05% | 352 |
|
|
2024
Q3 | $26.3M | Sell |
220,619
-83,724
| -28% | -$11.2M | 0.11% | 211 |
|
|
2024
Q2 | $43.4M | Sell |
304,343
-3,998
| -1% | -$530K | 0.19% | 119 |
|
|
2024
Q1 | $39.6M | Sell |
308,341
-15,413
| -5% | -$1.83M | 0.19% | 140 |
|
|
2023
Q4 | $33.5M | Sell |
323,754
-8,584
| -3% | -$849K | 0.16% | 173 |
|
|
2023
Q3 | $30.2M | Sell |
332,338
-482
| -0.1% | -$42.5K | 0.16% | 173 |
|
|
2023
Q2 | $26.9M | Sell |
332,820
-59,560
| -15% | -$4.87M | 0.13% | 196 |
|
|
2023
Q1 | $31.2M | Sell |
392,380
-67,862
| -15% | -$4.81M | 0.15% | 169 |
|
|
2022
Q4 | $31.1M | Sell |
460,242
-60,132
| -12% | -$3.53M | 0.15% | 179 |
|
|
2022
Q3 | $25.9M | Sell |
520,374
-16,612
| -3% | -$890K | 0.12% | 205 |
|
|
2022
Q2 | $29.9M | Buy |
536,986
+83,254
| +18% | +$4.62M | 0.13% | 190 |
|
|
2022
Q1 | $25.2M | Sell |
453,732
-2,768
| -0.6% | -$142K | 0.09% | 243 |
|
|
2021
Q4 | $25.6M | Buy |
456,500
+21,072
| +5% | +$1.14M | 0.1% | 230 |
|
|
2021
Q3 | $20.9M | Buy |
435,428
+5,094
| +1% | +$246K | 0.09% | 242 |
|
|
2021
Q2 | $18M | Buy |
430,334
+83,372
| +24% | +$3.23M | 0.08% | 272 |
|
|
2021
Q1 | $11.7M | Sell |
346,962
-183,398
| -35% | -$6.53M | 0.06% | 302 |
|
|
2020
Q4 | $18.5M | Sell |
530,360
-222,574
| -30% | -$7.69M | 0.11% | 223 |
|
|
2020
Q3 | $26.1M | Buy |
752,934
+59,608
| +9% | +$1.99M | 0.17% | 153 |
|
|
2020
Q2 | $22.7M | Buy |
693,326
+192,318
| +38% | +$6.14M | 0.16% | 170 |
|
|
2020
Q1 | $15.1M | Buy |
501,008
+446,808
| +824% | +$13.3M | 0.12% | 210 |
|
|
2019
Q4 | $1.57M | Buy |
54,200
+13,400
| +33% | +$371K | 0.01% | 637 |
|
|
2019
Q3 | $1.05M | Hold |
40,800
| – | – | 0.01% | 646 |
|
|
2019
Q2 | $1.04M | Hold |
40,800
| – | – | 0.01% | 644 |
|
|
2019
Q1 | $1.07M | Buy |
+40,800
| New | +$1M | 0.01% | 549 |
|
|
2013
Q3 | – | Sell |
-477,500
| Closed | -$7.4M | – | 621 |
|
|
2013
Q2 | $7.4M | Buy |
+477,500
| New | +$7.95M | 0.05% | 244 |
|
Other funds holding NVO
EHC
SRIM
MG
OAM
Calamos Advisors's NVO Position: Q2 2026 in Review
Calamos Advisors held its Novo Nordisk (NVO) position steady in Q2 2026 at 98,472 shares worth $4.72M. The position accounts for 0.02% of the portfolio, ranked #553.
Calamos Advisors first reported a position in NVO in Q2 2013 and has held it in 31 quarters since. The position peaked at $43.4M in Q2 2024. 819 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Calamos Advisors held 98,472 shares of Novo Nordisk worth $4.72M as of Q2 2026.
- Calamos Advisors left its Novo Nordisk share count unchanged in Q2 2026.
- Novo Nordisk made up 0.02% of Calamos Advisors's portfolio in Q2 2026, its #553 holding.
- Calamos Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 31 quarters since.
- Calamos Advisors's Novo Nordisk position peaked at $43.4M in Q2 2024.
- 819 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.